General Covered Indications
The following FDA-approved indications and compendial uses are covered when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.
ALL of the following
FDA-approved indications
Unresectable or metastatic melanoma in adult and pediatric patients 12 years and older, as a single agent or in combination with nivolumab.
Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
First-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma, in combination with nivolumab.
Treatment of adult and pediatric patients 12 years and older with unresectable or metastatic MSI-H or dMMR colorectal cancer, in combination with nivolumab.
First-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma, or treatment after prior sorafenib, in combination with nivolumab.
First-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 at 1% or greater, with no EGFR or ALK genomic tumor aberrations, in combination with nivolumab.
First-line treatment of adult patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
First-line treatment of adult patients with unresectable malignant pleural mesothelioma, in combination with nivolumab.
First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at 1% or greater, in combination with nivolumab.
Compendial uses
Adrenal gland tumors; ampullary adenocarcinoma; appendiceal neoplasms and cancers; biliary tract cancers, including cholangiocarcinoma and gallbladder cancer; bone cancer; central nervous system brain metastases; cervical cancer; colorectal cancer, including anal adenocarcinoma; cutaneous melanoma; esophageal or esophagogastric junction cancers; gastric cancer; gestational trophoblastic neoplasia; hepatocellular carcinoma; Kaposi sarcoma; Merkel cell carcinoma; non-small cell lung cancer; ovarian, fallopian tube, or primary peritoneal cancer; peritoneal or pleural mesothelioma; renal cell carcinoma; small bowel adenocarcinoma; soft tissue sarcoma, including angiosarcoma, borderline or malignant phyllodes tumor, dedifferentiated liposarcoma, epithelioid hemangioendothelioma, extremity or body wall sarcoma, head or neck sarcoma, pleomorphic rhabdomyosarcoma, and retroperitoneal or intra-abdominal sarcoma; uterine neoplasms, including endometrial carcinoma and uterine sarcoma; uveal melanoma; vaginal cancer; and vulvar cancer.
Adrenal Gland Tumors
Covered when the following criterion is met:
ALL of the following
Treatment is in combination with nivolumab for unresectable or metastatic adrenocortical carcinoma.Authorization: 6 months
Ampullary Adenocarcinoma
Covered when the following criterion is met:
ALL of the following
Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent for progressive or metastatic MSI-H or dMMR ampullary adenocarcinoma.Authorization: 6 months
Adrenal Gland Tumors — Combination and Disease Status
Covered when the following criterion is met:
ALL of the following
Treatment is in combination with nivolumab for unresectable or metastatic adrenocortical carcinoma.Authorization: 6 months
Ampullary Adenocarcinoma — Disease, Biomarker, and Regimen
Covered when ALL of the following are met:
ALL of the following
Disease is progressive or metastatic ampullary adenocarcinoma.
The tumor is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Appendiceal Neoplasms and Cancers
Covered when ALL of the following are met:
ALL of the following
Disease is an appendiceal neoplasm or appendiceal cancer, including appendiceal adenocarcinoma, goblet cell adenocarcinoma, or undifferentiated carcinoma not otherwise specified.
The tumor is MSI-H, dMMR, or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype, such as TMB greater than 50 mut/Mb.
Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Biliary Tract Cancer
Covered when either treatment setting and its associated requirements are met:
ANY of the following
Subsequent treatment
Disease is unresectable or gross residual (R2), or metastatic extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer.
The tumor is tumor mutational burden-high (TMB-H).
Treatment is in combination with nivolumab.
Neoadjuvant treatment
Disease is resectable, locoregionally advanced gallbladder cancer.
Bone Cancer
Covered when ALL of the following are met:
ALL of the following
Disease is unresectable or metastatic bone cancer.
Tumor is TMB-H, defined as at least 10 mut/Mb.
Disease has progressed following prior treatment and there are no satisfactory alternative treatment options.
Treatment is in combination with nivolumab.
Central Nervous System Brain Metastases
Covered when the following criteria are met:
ALL of the following
Member has CNS brain metastases from BRAF-nonspecific melanoma.
Treatment is a single agent or in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Cervical Cancer
Covered when ALL of the following are met:
ALL of the following
Treatment is in combination with nivolumab.
ANY of the following
Disease is recurrent or metastatic cervical cancer.
Disease is persistent small cell neuroendocrine carcinoma of the cervix.
Colorectal Cancer
Covered when ALL of the following are met:
ALL of the following
Disease is colorectal cancer, including anal adenocarcinoma.
The tumor is MSI-H, dMMR, or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype, such as TMB greater than 50 mut/Mb.
Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Cutaneous Melanoma
Covered in any of the following treatment settings:
ANY of the following
Single agent for up to 4 doses, or in combination with nivolumab for 4 doses followed by nivolumab as a single agent, for metastatic or unresectable disease.
In combination with nivolumab for up to 4 doses followed by nivolumab as a single agent as adjuvant treatment of oligometastatic disease when there is no evidence of disease following systemic or metastasis-directed therapy, such as complete resection.
Single agent for up to 8 doses as adjuvant treatment of local satellite or in-transit recurrence, resectable disease, or oligometastatic disease after prior anti-PD-1 therapy.
Low dose in combination with pembrolizumab for up to 4 doses followed by pembrolizumab as a single agent for disease progression following anti-PD-1 therapy as subsequent therapy for metastatic or unresectable disease.
Esophageal and Esophagogastric Junction Cancers
Covered when the applicable disease and treatment conditions are met:
ANY of the following
PD-L1-positive first-line or subsequent therapy
Member is not a surgical candidate or has unresectable locally advanced, recurrent, or metastatic esophageal or esophagogastric junction cancer.
Treatment is in combination with nivolumab.
ANY of the following
First-line therapy and PD-L1 is at least 1%.
Biomarker-defined disease
Gastric Cancer
Covered when ALL of the following are met:
ALL of the following
Disease is gastric adenocarcinoma.
Treatment is in combination with nivolumab.
Gestational Trophoblastic Neoplasia
Covered when ALL of the following are met:
ALL of the following
Disease is multiagent chemotherapy-resistant gestational trophoblastic neoplasia.
ANY of the following
Member has recurrent or progressive intermediate trophoblastic tumor, including placental site trophoblastic tumor or epithelioid trophoblastic tumor.
Member has high-risk disease.
Treatment is in combination with nivolumab.
Hepatocellular Carcinoma
Covered when either treatment setting is met:
ANY of the following
First-line treatment of unresectable or extrahepatic/metastatic hepatocellular carcinoma in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Subsequent treatment of hepatocellular carcinoma in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Kaposi Sarcoma
Covered when ALL of the following are met:
ALL of the following
Disease is advanced Kaposi sarcoma that is relapsed or refractory.
Treatment is subsequent therapy in combination with nivolumab.
Merkel Cell Carcinoma
Covered when the disease meets the specified stage or setting criteria:
ALL of the following
Disease is regional, in-transit, unresectable, recurrent, or stage IV Merkel cell carcinoma.
Treatment is a single agent or in combination with nivolumab.
Non-Small Cell Lung Cancer
Covered when ALL of the following are met:
ALL of the following
Disease is recurrent, advanced, or metastatic NSCLC.
There are no EGFR exon 19 deletions or exon 21 L858R mutations, and no ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.
The requested medication is used in a regimen containing nivolumab.
Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Covered when ALL of the following are met:
ALL of the following
Disease is progressive, persistent, or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, clear cell carcinoma of the ovary, or hypercalcemic type small cell carcinoma of the ovary.
Treatment is in combination with nivolumab.
Pleural or Peritoneal Mesothelioma
Covered when ALL of the following are met:
ALL of the following
Disease is pleural or peritoneal mesothelioma, including pericardial mesothelioma or tunica vaginalis testis mesothelioma.
Treatment is in combination with nivolumab.
Initial Therapy: Additional Covered Malignancies
The following additional malignancies are covered when the stated disease, biomarker, treatment setting, and regimen requirements are met. Authorization is generally for 6 months.
ANY of the following
Renal cell carcinoma: relapsed, advanced, or stage IV disease with clear cell histology; use in combination with nivolumab for 4 doses followed by single-agent nivolumab.
Small bowel adenocarcinoma: unresectable, medically inoperable, advanced, or metastatic disease, or neoadjuvant treatment; tumor is MSI-H, dMMR, or POLE/POLD1 with an ultra-hypermutated phenotype such as TMB greater than 50 mut/Mb; use in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
Soft tissue sarcoma: pleomorphic rhabdomyosarcoma, borderline or malignant phyllodes tumor of the breast, or epithelioid hemangioendothelioma with TMB-H of at least 10 mut/Mb, treated in combination with nivolumab; or angiosarcoma, dedifferentiated liposarcoma, extremity or body wall sarcoma, head or neck sarcoma, or retroperitoneal or intra-abdominal sarcoma treated in combination with nivolumab.
Uterine neoplasms: subsequent treatment of recurrent unresectable or metastatic endometrial carcinoma, or subsequent treatment of unresectable or metastatic uterine sarcoma, when TMB-H is at least 10 mut/Mb and there are no satisfactory alternative treatment options; use in combination with nivolumab.
Cutaneous Melanoma Continuation Limits
For continued treatment of cutaneous melanoma, authorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and the applicable maximum dose limit has not been reached.
ANY of the following
Single-agent adjuvant treatment of local satellite or in-transit recurrence, resectable disease, or oligometastatic disease.Up to 8 doses maximum
Combination with nivolumab for adjuvant treatment; neoadjuvant treatment; or single-agent, pembrolizumab, or nivolumab treatment for metastatic or unresectable disease.Up to 4 doses maximum
Neoadjuvant treatment.Up to 2 doses maximum
Tennessee State Mandate Requirements
BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of FDA-approved drugs.
ALL of the following
The off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.